Table S2 from The MATTERS Trial: Safety and Tolerability of Whole-Body Hyperthermia at 41.50°C in Combination with Chemotherapy in Metastatic Cancer Patients

Luigi Brancato; Ivana Gorbašlieva; Oleg M. Rudenko; Tine Logghe; Eke van Zwol; Gaëlle Boulet; Lien Van den Bossche; Johan Van den Bossche; Marc Peeters; T. Chapelle; Vera Saldien; Peter Vueghs; Timon Vandamme; Rowan Dankerlui; Dirk Ysebaert; Johannes Bogers

doi:10.1158/2767-9764.31248698

Table S2 from The MATTERS Trial: Safety and Tolerability of Whole-Body Hyperthermia at 41.50°C in Combination with Chemotherapy in Metastatic Cancer Patients

2026 Open access

Read full text

Authors: Luigi Brancato, Ivana Gorbašlieva, Oleg M. Rudenko, Tine Logghe, Eke van Zwol, Gaëlle Boulet, Lien Van den Bossche, Johan Van den Bossche, Marc Peeters, T. Chapelle, Vera Saldien, Peter Vueghs

+4 more

Timon Vandamme, Rowan Dankerlui, Dirk Ysebaert, Johannes Bogers

DOI: 10.1158/2767-9764.31248698

Cited by: 0

Abstract

Overview of adverse events (AE) reported during the study and assessed as related to TempoCure, whole-body hyperthermia or their combination, categorized by severity (CTCAE v5.0).

Fields of Study & Subjects

Ultrasound and Hyperthermia Applications Intraperitoneal and Appendiceal Malignancies Hepatocellular Carcinoma Treatment and Prognosis

Publication details

Publication date: 4 February 2026